Virbac SA
V16
Company Profile
Business description
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
Contact
13e rue
1ere avenue 2065, LID - BP 27
Carros06511
FRAT: +33 492087100
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
50
Stocks News & Analysis
stocks
Chart of the Week: Why ASX tech is poised for a comeback
The “SaaSpocalypse” never arrived. Now, software stocks are positioning for a long-awaited comeback.
stocks
Undervalued ASX share drives earnings growth despite AI fears
Early AI success lifts investor sentiment.
stocks
Weekly Earnings Wrap: CBA, REA Group, Westpac, Resmed and more
Property listings rebound, bank lending slows and growth stocks face heightened scrutiny as earnings season rolls on.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,404.70 | 0.80 | -0.01% |
| CAC 40 | 8,674.94 | 40.00 | -0.46% |
| DAX 40 | 26,331.07 | 60.35 | -0.23% |
| Dow JONES (US) | 53,770.27 | 21.58 | -0.04% |
| FTSE 100 | 10,833.15 | 11.04 | -0.10% |
| HKSE | 25,440.17 | 212.65 | -0.83% |
| NASDAQ | 26,588.49 | 143.04 | 0.54% |
| Nikkei 225 | 67,524.06 | 553.84 | 0.83% |
| NZX 50 Index | 13,737.66 | 123.00 | -0.89% |
| S&P 500 | 7,748.50 | 20.30 | 0.26% |
| S&P/ASX 200 | 9,209.40 | 2.20 | -0.02% |
| SSE Composite Index | 3,946.68 | 12.58 | 0.32% |